Med Hypotheses. 2009 Mar;72(3):333-7. Epub 2008 Nov 28.

Low-dose naltrexone for disease prevention and quality of life.

Source

Department of Humanities and Social Sciences, Embry-Riddle Aeronautical University, Daytona Beach, FL 32114, United States. NPHbrown@aol.com

Abstract

The use of low-dose naltrexone (LDN) for the treatment and prophylaxis of various bodily disorders is discussed. Accumulating evidence suggests that LDN can promote health supporting immune-modulation which may reduce various oncogenic and inflammatory autoimmune processes. Since LDN can upregulate endogenous opioid activity, it may also have a role in promoting stress resilience, exercise, social bonding, and emotional well-being, as well as amelioration of psychiatric problems such a autism and depression. It is proposed that LDN can be used effectively as a buffer for a large variety of bodily and mental ailments through its ability to beneficially modulate both the immune system and the brain neurochemistries that regulate positive affect.

PMID:: 19041189; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Cancer - MedlinePlus Health Information

Molecular Biology Databases

NALTREXONE - HSDB

Supplemental Content

Related citations

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. [Ann Neurol. 2010]
Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.
Cree BA, Kornyeyeva E, Goodin DS. Ann Neurol. 2010 Aug; 68(2):145-50.
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. [Mult Scler. 2010]
The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.
Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. Mult Scler. 2010 Aug; 16(8):964-9. Epub 2010 Jun 9.
Review The resolution of inflammation and cancer. [Cytokine Growth Factor Rev. 2010]
Review The resolution of inflammation and cancer.
Rodriguez-Vita J, Lawrence T. Cytokine Growth Factor Rev. 2010 Feb; 21(1):61-5. Epub 2009 Dec 22.
Reducing naltrexone-resistant hyperphagia using laser acupuncture to increase endogenous opiates. [Brain Inj. 1996]
Reducing naltrexone-resistant hyperphagia using laser acupuncture to increase endogenous opiates.
Read A, Beaty P, Corner J, Sommerville Ville C. Brain Inj. 1996 Dec; 10(12):911-9.
Review Oncogenic inflammation and autoimmune disease. [Autoimmun Rev. 2006]
Review Oncogenic inflammation and autoimmune disease.
Eisenlohr LC, Rothstein JL. Autoimmun Rev. 2006 Dec; 6(2):107-14. Epub 2006 May 22.

See reviews... See all...

Chemical compound information

Naltrexone

MW: 341.40 g/mol

MF: C₂₀H₂₃NO₄

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Low-dose naltrexone for disease prevention and quality of life.
Low-dose naltrexone for disease prevention and quality of life.
Med Hypotheses. 2009 Mar ;72(3):333-7. Epub 2008 Nov 28 .

PubMed
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
Blood. 2009 Apr 16 ;113(16):3679-81. Epub 2009 Feb 20 .

PubMed
Transgenic mice enriched in omega-3 fatty acids are more susceptible to pulmonar...
Transgenic mice enriched in omega-3 fatty acids are more susceptible to pulmonary tuberculosis: impaired resistance to tuberculosis in fat-1 mice.
J Infect Dis. 2010 Feb 1 ;201(3):399-408.

PubMed
Matrix metalloproteinases: they're not just for matrix anymore!
Matrix metalloproteinases: they're not just for matrix anymore!
Curr Opin Cell Biol. 2001 Oct ;13(5):534-40.

PubMed
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Science. 2002 Mar 29 ;295(5564):2387-92.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: